

Advancing High-Potency API Capabilities

To strengthen our position in complex, high-value pharmaceuticals, we inaugurated a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) Laboratory at our Integrated Innovation Centre in Pune.

The cGMP-compliant facility is equipped with advanced OEB-5 containment isolators, enabling the safe development of highly potent molecules for specialised therapeutic areas, including oncology. Designed to support next-generation modalities such as Antibody Drug Conjugates (ADCs), Peptide Drug Conjugates (PDCs) and PROTACs, the laboratory enhances our capabilities across route scouting, process optimisation, Quality by Design (QbD), polymorph studies, analytical development, regulatory support and early- to late-phase clinical development.

Integrated with Hikal's existing process safety, solid-state and flow chemistry capabilities, the laboratory provides end-to-end development support at laboratory scale, from milligrams to approximately 200 grams per batch. Dedicated clean-room infrastructure, in-house analytical systems and particle size control further strengthen operational efficiency while minimising contamination risks.

The investment reinforces Hikal's ability to develop differentiated APIs, expand high-value CDMO opportunities and build a future-ready pharmaceutical portfolio driven by innovation and scientific excellence.

Impact at a Glance

- Strengthened capabilities in high-potency and complex API development
- Enabled development of advanced modalities, including ADCs, PDCs and PROTACs
- Enhanced end-to-end R&D and clinical development capabilities
- Expanded opportunities in specialised therapeutics and high-value CDMO partnerships

